Read More Pharma Industry News Harbour BioMed resubmits BLA for batoclimab to China’s NMPA for generalized myasthenia gravis Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application… byPallavi MadhirajuJune 27, 2024